|
Video: What is a Stock Split?
|
|
Akouos is a genetic medicine company, engaged in developing gene therapies to restore, improve, and preserve physiologic hearing for individuals who live with disabling hearing loss. Co. has a genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus used in gene therapy, known as adeno-associated virus, and a delivery approach. Co. is developing its product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of etiology, such as AK-antiVEGF for vestibular schwannoma. According to our AKUS split history records, AKUS has had 0 splits. | |
|
AKUS (AKUS) has 0 splits in our AKUS split history database.
Looking at the AKUS split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AKUS shares, starting with a $10,000 purchase of AKUS, presented on a split-history-adjusted basis factoring in the complete AKUS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/29/2020 |
|
End date: |
12/01/2022 |
|
Start price/share: |
$22.37 |
|
End price/share: |
$13.29 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-40.59% |
|
Average Annual Total Return: |
-19.33% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,940.30 |
|
Years: |
2.42 |
|
|
|
|
|